Introduction
Dasatab 20 mg (Dasatinib) Tablet is a highly effective tyrosine kinase inhibitor designed for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) and acute lymphoblastic leukemia (Ph+ ALL). Manufactured by Eskayef Pharmaceuticals Ltd. and supplied globally by Onco Solution, Dasatab 20 mg (Dasatinib) Tablet targets BCR-ABL and SRC family kinases, offering a potent therapeutic option for patients resistant or intolerant to prior therapies. With its proven efficacy and manageable safety profile, Dasatab 20 mg (Dasatinib) Tablet is a cornerstone in modern oncology protocols.
Indications
Dasatab 20 mg (Dasatinib) Tablet is indicated for:
- Newly Diagnosed Ph+ CML: Chronic phase in adults and pediatric patients ≥1 year.
- Resistant/Intolerant Ph+ CML: Chronic, accelerated, or blast phase in adults.
- Ph+ ALL: Adults with resistance or intolerance to prior therapy.
- Pediatric Ph+ CML: Chronic phase in children ≥1 year.
Pharmacology
Dasatab 20 mg (Dasatinib) Tablet exerts its therapeutic effects by:
- Inhibiting BCR-ABL, SRC family kinases (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRβ.
- Overcoming resistance to imatinib through binding to multiple conformations of the ABL kinase.
- Inducing apoptosis in Ph+ CML and ALL cell lines.
Pharmacokinetics:
- Absorption: Peak plasma concentrations achieved within 0.5–6 hours.
- Distribution: 96% plasma protein binding; apparent volume of distribution: 2505 L.
- Metabolism: Primarily by CYP3A4; active metabolite contributes 5% of total AUC.
- Excretion: 85% fecal and 4% renal excretion within 10 days.
